Gould Robert J
SEC Form 4 insider trading activity
Gould Robert J has filed 4 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: Feb 4, 2026.
On the most recent filing, Gould Robert J is listed as Director at Fulcrum Therapeutics, Inc. Inside the rolling window, Gould Robert J reported no open-market purchases and 3 open-market sales totaling $668K in FULC. The largest disclosed transaction in the window is a sale of 30,000 FULC shares on Jan 2, 2026, worth $341K.
Companies traded
Other insiders at FULC
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$668K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Gould Robert J made?
Gould Robert J has filed 4 SEC Form 4 filings (4 transaction rows) across 1 company since 2025.
Which companies does Gould Robert J trade?
Gould Robert J has filed SEC Form 4 disclosures for 1 company, including FULC.
When was Gould Robert J's most recent SEC Form 4 filing?
Gould Robert J's most recent SEC Form 4 filing on Tracefour is dated Feb 4, 2026.
What is Gould Robert J's total buy and sell value in the current window?
Inside the rolling retention window, Gould Robert J bought $0 and sold $668K based on SEC Form 4 filings.
What was Gould Robert J's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 30,000 FULC shares on 2026-01-02, worth $341K, per SEC Form 4 filings.